Sensorion (ALSEN.PA) Stock Price
Sensorion Price
Over the last 13 years Sensorion grew revenue by 164.9% annually, reaching 6.65 M EUR. For Sensorion, the net margin of -390.4% is down versus -381.7% a few years ago. The consensus 12-month price target for Sensorion is 2.04 EUR, about 68.5% below where the stock trades today. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus.
Sensorion stock price
Sensorion business model & stock analysis
Frequently asked questions about Sensorion
Sensorion SA is a biopharmaceutical company specializing in the development of innovative therapies to address inner ear disorders. The company's business model revolves around the research, development, and commercialization of novel treatments for conditions such as vertigo and hearing loss. Sensorion SA aims to leverage its expertise in inner ear biology and drug development to create innovative therapies that can provide significant benefits to patients. With a focus on advancing its proprietary pipeline of drug candidates, Sensorion SA is dedicated to meeting the unmet medical needs in the field of inner ear disorders.
Sensorion SA is primarily active in the biotechnology industry.
The main competitors of Sensorion SA in the market are [competitor #1], [competitor #2], and [competitor #3]. These companies operate in the same industry as Sensorion SA and provide similar products or services. Despite facing competition, Sensorion SA has positioned itself as a key player in the market with its unique offerings. By continually innovating and delivering high-quality solutions, Sensorion SA maintains a competitive edge in the industry.
Sensorion SA is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for inner ear disorders. Founded in 2009, Sensorion has a strong focus on addressing unmet medical needs in the field of hearing loss and vestibular disorders. The company's research and development efforts primarily revolve around the identification, selection, and development of small molecules designed to protect, regenerate, and restore inner ear cells. With a deep commitment to improving the quality of life for patients suffering from hearing and balance disorders, Sensorion SA continues to pursue groundbreaking solutions to these debilitating conditions.
Sensorion SA, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed Phase 1 clinical trials for its novel therapy targeting inner ear disorders. It also received Orphan Drug Designation from the FDA for its product candidate, confirming its potential to address unmet medical needs. Furthermore, Sensorion SA successfully initiated Phase 2 clinical trials, demonstrating promising results in patients with sudden sensorineural hearing loss. The company's collaborations with renowned academic institutions highlight its commitment to advancing research in the field. Overall, Sensorion SA's achievements reflect its dedication to revolutionizing treatments for inner ear disorders, positioning it as a key player in the industry.
Sensorion SA is primarily present in several countries and regions globally. These include the United States, Europe, and Asia. The company has established a strong presence in the United States, where it conducts significant research and development activities. In Europe, Sensorion SA has partnerships and collaborations with various academic institutions and pharmaceutical companies. Additionally, the company has expanded its reach in Asia through strategic alliances and distribution agreements. With its global presence, Sensorion SA aims to address the unmet medical needs of patients suffering from inner ear disorders and provide innovative solutions in the field of hearing and balance disorders.
Sensorion SA is a leading biopharmaceutical company dedicated to developing innovative therapies for inner ear disorders. The company's values revolve around scientific excellence, patient-centered approach, and commitment to improving the lives of individuals suffering from vestibular and hearing impairments. Sensorion SA aims to provide effective and safe treatment solutions while prioritizing the needs and well-being of patients. With a strong corporate philosophy grounded in research and development, Sensorion SA strives to address the unmet medical needs in the field of auditory disorders, aiming to make a meaningful impact on the lives of individuals affected by these conditions.
Analysts currently set an average price target of 1.94 EUR for the Sensorion stock (median: 2.04 EUR), implying -70.1 % versus the latest price. The consensus is based on 13 analyst ratings.
14 analysts currently rate the Sensorion stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Sensorion to generate revenue of 4.55 M EUR and earnings per share of -169.83 EUR.
The Sensorion share (ALSEN.PA) is listed on 5 stock exchanges, including: Frankfurt (RFM.F), München (RFM.MU), Düsseldorf (RFM.DU), Paris (ALSEN.PA).
Sensorion SA is a French biotechnology company specializing in the development of novel therapies for the treatment of inner ear disorders and hearing loss. The company focuses on researching and developing drugs tailored to the specific needs of patients. Sensorion aims to create innovative products and therapies in the field of otolaryngology to meet the needs of patients.
The expected revenue of Sensorion is 4.55 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Sensorion is -1.02 B EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Sensorion is currently -0.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sensorion stock.
The price-to-sales ratio (P/S) of Sensorion is currently 8.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sensorion stock.
The Eulerpool Quality Score for Sensorion is 2/10.
The ISIN of Sensorion is FR0012596468. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Sensorion is A14SVV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Sensorion is ALSEN.PA. The ticker symbol is used to trade Sensorion shares on the stock exchange.
Sensorion stock
Sensorion Peer Group
Sensorion Ticker
Sensorion FIGI
All fundamentals and in-depth analysis of Sensorion
Our stock analysis for Sensorion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sensorion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.